C.R. Jackson
Biotech, healthcare, value, research analyst

Why Is BioCryst Pharmaceuticals At 52 Week High Levels?

On August !, 2013, BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) disclosed in a regulatory filing that on July 31, the company was notified by the United States Food and Drug Administration (FDA) that the agency lifted the clinical hold placed on its hereditary angioedema (NYSE:HAE) drug BCX 4161. The FDA notified BioCryst that the complete response letter (NYSE:CRL) submitted by BioCryst in response to the hold satisfactorily addressed its concerns. BioCryst can now conduct clinical trials in the United States to further the development of BCX 4161. BioCryst stock was up over 20% after the news.

On July 30-31, BioCryst announced to sell up to 4 million shares of stock at $4.40 per share to raise...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details